Patent applications published 23 March 2011
Selected patent applications from the weekly European Patents Bulletin
- Immunomodulation by IAP inhibitors
Novartis; Dana Farber Cancer Institute 229650*
- 5-hydroxylmethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
Actelion Pharmaceuticals 2296651*
- Topical regional neuro-affective therapy
Afgin Pharma 2296652*
- Compounds and methods for treating inflammatory and fibrotic disorders
Intermune 2296653*
- 8-hydroxyquinoline derivatives for the treatment of haematological malignancies
University Health Network; The Governing Council of the University of Toronto 2296654*
- Quinolynylmethylimidazoles as therapeutic agents
Allergan 2296655*
- Dihydrotetrabenanzine for the treatment of anxiety
Bioavail Laboratories International (Barbados) 2296656*
- Method of treating anxious major anxiety disorder
AstraZeneca 2296657*
- NMDA receptor antagonists for the treatment of neuropsychiatric disorders
Emory University 2296658*
- Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
Janssen Pharmaceutica 2296659*
- Anti-tumour compsns and methods
Prendergast, Patrick T 2296660*
- SGC stimulators, SGC activators and combinations thereof for the treatment of hearing impairment
Bayer Schering Pharma 2296661*
- Inhibitors of PLK
Chroma Therapeutics 2296662*
- Combinations comprising methotrexate and DHODH inhibitors
Almirall 2296663*
- An inhibitor of anti-apoptotic proteins
Burnham Institute for Medical Research 2296664*
- Pharmaceutical compsn for the treatment of premature ejaculation
Yuhan 2296665*
- Use of FTS for the treatment of myocardial ischaemia/reperfusion injury
Ramot at Tel-Aviv University 2296666*
- Silicone compsn
Momentive Performance Materials 2296667*
- Compsns for the treatment of hair loss
Bouras, Elias 2296668*
- Targeted oligonucleotide compsns for modifying gene expression
Yale University 2296669*
- Glycosaminoglycan oral use and compsns
P4P International 2296670*
- Zeolite formulation and use thereof for the prevention and therapy of diseases caused by infections with herpes simplex virus
Ruder Boskovic Institute 2296671*
- Conditioned medium of liver progenitor cells
Fresenius Medical Care Deutschland 2296672*
- Colostrum-derived fraction for wound healing and skin care
Kjelden, Dustin; Kjelden, Randy; Drouin, Réjean; Juneau, Christina; Moroni, Olivier 2296673*
- Novel adult progenitor cell
University College Cardiff 2296674*
- Echinoderm-derived extracts, methods of preparation and uses thereof
Rival 2296675*
- Cellular extracts
Regenics 2296676*
- Modulating interstitial pressure and oncolytic viral delivery and distribution
Oncolytics Biotech 2296678*
- Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
Oncolytics Biotech 2296679*
- Labisia pumila extracts for reducing the risk of cardiovascular diseases
Government of Malaysia, as represented by The Ministry of Science, Technology and Innovation 2296680*
- Methods of treating ophthalmic disorders
Nikken Sohonsha; Tel HaShomer Medical Research Infrastructure and Services 2296682*
- Methods of treating inflammatory disease and managing symptoms thereof
University of Rochester 2296683*
- Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
Xigen 2296684*
- Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
Synergy Pharmaceuticals 2296685*
- Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
Ferring International Center 2296686*
- Pharmaceutical compsns of somatostatin-dopamine conjugates
Ipsen Pharma 2296687*
- Peptide vaccine for influenza virus
Glykos Finland 2296688*
- Methods of treatment utilising binding proteins of the interleukin-21 receptor
Wyeth 2296689*
- FGF21 mutants and uses thereof
Amgen 2296690*
- Use of pegylated type III interferons for the treatment of hepatitis C
ZymoGenetics 2296691*
- Isoform-specific insulin analogues
Case Western Reserve University 2296692*
- Compsns for enhancing the antibacterial activity of myeloeroxidase and methods of use thereof
Exoxemis 2296693*
- Neutralizing proprotein convertase kexin type 9 (PCSK9) variants and uses thereof
Amgen 2296694*
- Nanoparticles containing proteolytic enzymes for the treatment of Peyronie’s disease
Santana, Cristiano Alberto Ribeiro; Pacaembu 2296695*
- Compsns comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
ImmunoVaccine Technologies 2296696*
- Immunogenic peptides derived from the midkine protein, as an anticancer vaccine
Commisariat à l’Énergie Atomique et aux Énergies Alternatives 2296697*
- Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
The USA as represented by the Secretary of the Army 2296699*
- Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens
Vaxin 2296700*
- Cell-based systems for producing influenza vaccines
Flugen 2296701*
- Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
FIT Biotech 2296702*
- IGF-II/GF-IIE binding proteins
Dyax; Commonwealth Scientific & Industrial Research Organisation 2296703*
- Mechanism of action of primary cell derived biologic
IRX Therapeutic 2296704*
- CCL20-specific antibodies for cancer therapy
Hadasit Medical Research Services & Development 2296705*
- Photochemical internalisation of kinase inhibitors
PCI Biotech 2276706*
- Compounds suited as nanocarriers for active agents and their use
Freie Universität Berlin; Ramot at Tel-Aviv University 2296707*
- Polymeric carrier
University of Washington; Phaserx 2296708*
- Modified release niacin formulations
Dr Reddy’s Laboratories Ltd; Dr Reddy’s Laboratories Inc 2296709*
- Modified protein excipient for delayed-release tablet
University Laval 2296710*
- Multi-arm amines and uses thereof
MDRNA 2296711*
- Amphiphilic block copolymers for nucleic acid delivery
Biocompatibles UK 2296712*
- 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
F Hoffmann-La Roche 2297081*
- Therapeutic compounds
Allergan; Donde, Yariv; Nguyen, Jeremiah 2297084*
- Substituted arylcyclopentenes as therapeutic agents
Allergan 2297085*
- Solid states of O-desmethylvenlafaxine salts
Teva Pharmaceutical Industries 2297087*
- New compounds with activity that protects agonist the action of toxins and viruses in intracellular action mode
Commisariat à l’Énergie Atomique et aux Énergies Alternatives 2297088*
- Benzocycloheptane and nenzoxepine derivatives
Janssen Pharmaceutica 2297089*
- Stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester
Teva Pharmaceutical Industries 2297090*
- Polymorphic and amorphous forms of lacosamide and amorphous compsns
Pliva Hrvatska 2297092*
- Novel amino acid derivatives, method for preparing same, and therapeutic use thereof
Pharmaleads 2297095*
- Compounds and compsns useful for the treatment of malaria
IRM LLC 2297097*
- Pyrrolidine derivatives as NK2 receptor antagonists
F Hoffmann-La Roche 2297098*
- 3-cyanoalkyl- and 3-hydroxyalkyl-lindoles and use thereof
Bayer Schering Pharma 2297099*
- Tetrahydrocyclopenta[B]indole androgen receptor modulators
Eli Lilly 2297100*